1De Vault KR, Castell DO. American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol, 2005,100:190-200.
2Fock KM,Talley N,Hunt R,et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol, 2004, 19:357-367.
3Moss SF, Armstrong D, Arnold R, et al. GERD 2003-a consensus on the way ahead. Digestion, 2003, 67:111-117.
4Bautista JM. The rising trend of on-demand and intermittent proton pump inhibitor therapy in gastroesophageal reflux disease:What is the evidence? J Gastroenterol Hepatol, 2006, 21(Suppl 5):S112-S114.
5Goh KL. “On-demand”therapy for gastroesophageal reflux disease: Are current proton pump inhibitors good candidates? J Gastroenterol Hepatol, 2006, 21(Suppl 5) :S115-S118.
6Cheung TK, Wong BC. Proton-pump inhibitor failure/resistance: Proposed mechanisms and therapeutic algorithm. J Gastroenterol Hepatol, 2006, 21(Suppl 5):S119-S124.
7Hallerback B, Unge P, Carling L, et al. Omeprazole or raniti-dine in long-term treatment of reflux esophagitis. Gastro-enterology,1994,107:1305-1311.
8Dent J,Yeomans N, Mackinnon M,et al. Omeprazole vs. rani tidine for prevention of relapse in reflux oesophagitis. A controlled double-blind trial of their efficacy and safety. Gut, 1994,35:590-598.
9Ang TL,Fock KM. Nocturnal acid breakthrough:Clinical significance and management. J Gastroenterol Hepatol, 2006,21(Suppl 5): S125-S128.
10Triadafilopoulos G, Dibaise JK, Nostrant TT, et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow up of the U.S.open label trail. Gastrointest Endosc, 2002,55:149-156.
